Now showing items 1-3 of 3

    • CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer. 

      Mostafid, AH; Porta, N; Cresswell, J; Griffiths, TRL; Kelly, JD; Penegar, SR; Davenport, K; McGrath, JS; Campain, N; Cooke, P; Masood, S; Knowles, MA; Feber, A; Knight, A; Catto, JWF; Lewis, R; Hall, E (2020-06)
      Objectives To evaluate the activity of intravesical mitomycin-C (MMC) to ablate recurrent low-risk non-muscle-invasive bladder cancer (NMIBC) and assess whether it may enable patients to avoid surgical intervention for ...
    • Pan-cancer deconvolution of tumour composition using DNA methylation. 

      Chakravarthy, A; Furness, A; Joshi, K; Ghorani, E; Ford, K; Ward, MJ; King, EV; Lechner, M; Marafioti, T; Quezada, SA; Thomas, GJ; Feber, A; Fenton, TR (2018-08-13)
      The nature and extent of immune cell infiltration into solid tumours are key determinants of therapeutic response. Here, using a DNA methylation-based approach to tumour cell fraction deconvolution, we report the integrated ...
    • Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment. 

      Wong, YNS; Joshi, K; Khetrapal, P; Ismail, M; Reading, JL; Sunderland, MW; Georgiou, A; Furness, AJS; Ben Aissa, A; Ghorani, E; Oakes, T; Uddin, I; Tan, WS; Feber, A; McGovern, U; Swanton, C; Freeman, A; Marafioti, T; Briggs, TP; Kelly, JD; Powles, T; Peggs, KS; Chain, BM; Linch, MD; Quezada, SA (2018-11)
      Despite the advances in cancer immunotherapy, only a fraction of patients with bladder cancer exhibit responses to checkpoint blockade, highlighting a need to better understand drug resistance and identify rational ...